In a pandemic, three critical things need to be developed quickly: diagnostics, therapeutics and vaccines. Transient expression of antibodies and other proteins offers an important tool for rapid scale-up and production. It is a well-established technique that, if applied correctly, could make future pandemic responses quicker.
In this presentation, our CSO Dr. Ian Wilkinson describes recent advances in large-scale transient expression and explores how implementation challenges can be overcome. He also covers how Absolute Antibody used transient expression to rapidly scale production of engineered coronavirus antibodies during the COVID-19 pandemic. Please enter your contact information below to view the video.